Testosterone Therapy in Type 2 Diabetes Mellitus Patients with Erectile Dysfunctio

Phase 2

• Conditions: Erectile dysfunction.; Male erectile disorder; F52.21

• Registration Number: IRCT20181106041575N1
• Lead Sponsor: Research and technology deputy of Mashhad University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 26 August 2019

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 66

Inclusion Criteria

Presence of Erectile dysfunction
Presence of Type 2 Diabetes Mellitus
Normal Serum Testosterone level
IIEF=<16

Exclusion Criteria

Contraindication for Tadalafil consumption including: Heart disease, Hypertension and Nitrocontin consumption
Contraindication for Tadalafil consumption including: liver disorder and prostate cancer

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Erectile dysfunction according to The International Index of Erectile Function (IIEF-5). Timepoint: International Index of Erectile Function (IIEF-5) was completed before, 3-month, and 6-month after the intervention. Method of measurement: erectile dysfunction according to The International Index of Erectile Function (IIEF-5).

Secondary Outcome Measures

Name	Time	Method
The side-effects of the intervention. Timepoint: before and 3-month after the intervention. Method of measurement: the side-effects of the intervention was measured using laboratory findings including liver function test, complete blood count (CBC), liver function test (LFT), fasting blood sugar and Prostate-specific antigen (PSA).